ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Hemorrhoid risk among people with diabetes mellitus using glucose lowering agents.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated whether there is an association between using antidiabetic agents (ADAs) or insulin and hemorrhoid risk among people with diabetes mellitus (DM). We have essentially used a massive dataset to identify a statistical association between ADAs and hemorrhoidal disease. The hazard ratios (HRs) and 95% confidence intervals (CIs) for hemorrhoids were estimated using univariate and multivariate Cox proportional hazards models. Covariates used in the multivariate models included age, sex, comorbidities, and medications. A total of 126,897 patients who had DM between 2009 and 2016 were involved in this study. The joint effect analysis showed that anyone receiving medication therapy with dipeptidyl peptidase IV (DPP IV) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2i) can significantly lower the risk of hemorrhoid with the adjusted HR (aHR) of 0.64, 95% CI=0.62-0.67; aHR of 0.29, 95% CI=0.24-0.35; and aHR of 0.14, 95% CI=0.11-0.18, respectively. We found that SGLT2i is more potent for hemorrhoid prophylaxis in incidence rate among DM patients.
Indexed as
Identifiers
40504374What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.